Catheter Precision Secures LockeT Orders and First German VIVO Placement
Fort Mill, S.C. – August 27, 2026 Catheter Precision, Inc. announced several commercial milestones for its LockeT® and VIVO™...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Fort Mill, S.C. – August 27, 2026 Catheter Precision, Inc. announced several commercial milestones for its LockeT® and VIVO™...
BOSTON, April 24, 2026 Haemonetics Corporation has announced compelling new clinical data demonstrating the safety, efficacy, and superior performance...
BOSTON, March 30, 2026 In a significant advancement for interventional cardiology and electrophysiology procedures, Haemonetics Corporation announced that the...
